The Metabolic Hegemon’s Strategic Pivot: A Comprehensive Analysis of Novo Nordisk and the 2026 Valuation Reset
Why Novo Nordisk (NVO) Just Cut Prices by 50% The global pharmaceutical landscape is currently navigating a period of profound structural transformation, centered on the evolution of cardiometabolic medicine. At the forefront of this shift is Novo Nordisk, a centenarian institution that has transitioned from a niche provider of bovine insulin to a multi-trillion-dollar arbiter…
Read more